

# References

## Chapter 38

- 1 Sari AB, Sheldon TA, Cracknell A, Turnbull A, Dobson Y, Grant C, Gray W, Richardson A. Extent, nature and consequences of adverse events: results of a retrospective casenote review in a large NHS hospital. *Quality & Safety in Health Care*. 2007;**16**:434–9.
- 2 Vandenbroucke JP, Psaty BM. Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. *Journal of the American Medical Association*. 2008;**300**(20):2417–19.
- 3 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Pharmacovigilance Planning E2E. November 2004. Available from: [http://www.ich.org/fileadmin/Public\\_Web\\_Site/ICH\\_Products/Guidelines/Efficacy/E2E/Step4/E2E\\_Guideline.pdf](http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2E/Step4/E2E_Guideline.pdf) (last accessed 18 November 2015).
- 4 European Commission. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 Amending, as Regards Pharmacovigilance, Directive 2001/83/EC on the Community Code Relating to Medicinal Products for Human Use. Available from: <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=O-J:L:2010:348:0074:0099:EN:PDF> (last accessed 18 November 2015).
- 5 European Commission. Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010 Amending, as Regards Pharmacovigilance of Medicinal Products for Human Use, Regulation (EC) No 726/2004 Laying Down Community Procedures for the Authorisation and Supervision of Medicinal Products for Human and Veterinary Use and Establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on Advanced Therapy Medicinal Products. Available from: <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0001:0016:EN:PDF> (last accessed 18 November 2015).
- 6 European Medicines Agency. Guideline on Good Pharmacovigilance Practices (GVP): Module V – Risk Management Systems (Rev. 1). June 2012. Available from: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Scientific\\_guideline/2012/06/WC500129134.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129134.pdf) (last accessed 18 November 2015).
- 7 Raschi E, Poluzzi E, Godman B, Koci A, Moretti U, Kalaba M, et al. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. *PLoS ONE*. 2013;**8**(11):e81208.
- 8 Sessler NE, Downing JM, Kale H, Chilcoat HD, Baumgartner TF, Coplan PM. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. *Pharmacoepidemiology & Drug Safety*. 2014;**23**(12):1238–46.
- 9 Layton D, Hazell L, Shakir SA. Modified prescription-event monitoring studies: a tool for pharmacovigilance and risk management. *Drug Safety*. 2011;**34**:e1–9.
- 10 European Medicines Agency. European Public Assessment Report (EPAR): Acomplia. EPAR Summary for the Public. Available from: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Summary\\_for\\_the\\_public/human/000666/WC500021282.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000666/WC500021282.pdf) (Accessed 2015 February 15)
- 11 Forslund T, Raaschou P, Hjendahl P, Krakau I, Wettermark B. Usage, risk, and benefit of weight-loss drugs in primary care. *Journal of Obesity*. 2011;459263.
- 12 European Commission. A Guideline on Summary of Product Characteristics. Available from: [http://ec.europa.eu/health/files/eudralex/vol-2/c/smpc\\_](http://ec.europa.eu/health/files/eudralex/vol-2/c/smpc_)

- guideline\_rev2\_en.pdf (last accessed 18 November 2015).
- 13** European Medicines Agency. Guideline on Good Pharmacovigilance Practices (GVP): Module XVI – Risk Minimisation Measures: Tools and Effectiveness of Indicators. June 2013. Available from: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Scientific\\_guideline/2013/06/WC500144010.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/06/WC500144010.pdf) (last accessed 18 November 2015).
  - 14** Mol PG, Straus SM, Piening S, de Vries JT, de Graeff PA, Haaijer-Ruskamp FM. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009. *Drug Safety*. 2010;**33**:463–74.
  - 15** Panorama. The secrets of seroxat. BBC News. Available from: <http://news.bbc.co.uk/2/hi/programmes/panorama/2310197.stm> (last accessed 18 November 2015).
  - 16** Reber KC, Piening S, Wieringa JE, Straus SM, Raine JM, de Graeff PA, et al. When direct health-care professional communications have an impact on inappropriate and unsafe use of medicines. *Clinical Pharmacology & Therapeutics*. 2013;**93**:360–5.
  - 17** Prieto L, Spooner A, Hidalgo-Simon A, Rubino A, Kurz X, Arlett P. Evaluation of the effectiveness of risk minimization measures. *Pharmacoepidemiology & Drug Safety*. 2012;**21**:896–9.
  - 18** Donabedian A. The quality of care. How can it be assessed? *Journal of the American Medical Association*. 1988;**260**:1743–8.
  - 19** Hoven JL, Haaijer-Ruskamp FM, Vander Stichele RH; DURQUIM Scientific Committee. Indicators of prescribing quality in drug utilisation research: report of a European meeting (DURQUIM, 13–15 May 2004). *European Journal of Clinical Pharmacology*. 2005;**60**:831–4.
  - 20** Sidorenkov G, Haaijer-Ruskamp FM, de Zeeuw D, Bilo H, Denig P. Review: relation between quality-of-care indicators for diabetes and patient outcomes: a systematic literature review. *Medical Care Research and Review*. 2011;**68**:263–89.
  - 21** Piening S, Haaijer-Ruskamp FM, de Graeff PA, Straus SM, Mol PG. Healthcare professionals' self-reported experiences and preferences related to direct healthcare professional communications: a survey conducted in the Netherlands. *Drug Safety*. 2012;**35**:1061–72.
  - 22** Leal I, Romio SA, Schuemie M, Oteri A, Sturkenboom M, Trifirò G. Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone. *British Journal of Clinical Pharmacology*. 2013;**75**(3):861–8.
  - 23** European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ENCePP Resource Database. Available from: <http://www.encepp.eu/encepp/resourcesDatabase.jsp> (last accessed 18 November 2015).
  - 24** Pharmacoepidemiological Research on Outcome of Therapeutics by a European Consortium (PROTECT). Drug Consumption Databases in Europe. Available from: <http://www.imi-protect.eu/drugConsumption.shtml> (last accessed 18 November 2015).
  - 25** Briesacher BA, Soumerai SB, Zhang F, Toh S, Andrade SE, Wagner JL, et al. A critical review of methods to evaluate the impact of FDA regulatory actions. *Pharmacoepidemiology & Drug Safety*. 2013;**22**(9):986–94.
  - 26** Piening S, Haaijer-Ruskamp FM, de Vries JT, van der Elst ME, de Graeff PA, Straus SM, Mol PG. Impact of safety-related regulatory action on clinical practice: a systematic review. *Drug Safety*. 2012;**35**:373–85.
  - 27** Valuck RJ, Libby AM, Orton HD, et al. Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. *American Journal of Psychiatry*. 2007;**164**:1198–205
  - 28** Ramsay CR, Matowe L, Grilli R, Grimshaw JM, Thomas RE. Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behavior change strategies. *International Journal of Technology Assessment in Health Care*. 2003;**19**:613–23.
  - 29** Zuckerman IH, Lee E, Wutoh AK, Xue Z, Stuart B. Application of regression-discontinuity analysis in pharmaceutical health services research. *Health Services Research*. 2006;**41**:550–63.